efforts, where healthcare providers play a vital role in these efforts. Findings from this study can inform strategies to improve screening and follow-up rates in HIV-infected individuals.
H uman papillomavirus (HPV) is one of the most common sexually transmitted infections in the United States. It is transmitted through sexual contact, which is also the most common mode of transmission for human immunodeficiency virus (HIV), where coinfection with HIV and HPV is common. 1, 2 Human papillomavirus infection is also a significant cause of anal cancer and precancerous intraepithelial lesions and is associated with 80% of anal cancer cases in the United States. 1, 3, 4 Because of immunosuppression, HPV-related anal cancer occurs in excess rates in persons with HIV/acquired immunodeficiency syndrome. 5, 6 The global incidence of anal cancer for the general population ranges from 0.1 to 2.8 cases per 100 000 persons/year among men and 0.0 to 2.2 cases per 100000 persons/year among women. 7 Anal cancer in the United States is also generally rare with an overall incidence of 0.9 cases per 100000 persons/year. However, individuals infected with HIV have the highest incidence for anal cancer and carry the greatest burden of anal cancer rates compared with the general HIV-uninfected population. 6, 8 A meta-analysis found that HIV-infected men and women are 28 times more likely to be given a diagnosis of anal cancer than the general HIV-uninfected population. 9 Specifically, HIV-infected men who have sex with men (MSMs) are at the greatest risk for anal cancer (adjusted incidence rate of 80.3 per 100 000 persons/year) and are more likely to have anal HPV infection than HIV-uninfected men. 1, 10 A study with a sample of HIV-infected MSMs found anal HPV infection to be as high as 93% compared with 60% of HIV-uninfected MSMs. 11 Anal cancer is also a significant cause of mortality in HIVinfected individuals. 6 The overall 5-year survival rate for the general population for localized disease is 78% compared with 18% for distant disease, where cancer-specific mortality has not been found to differ by HIV status. 12, 13 Of concern is that, since the introduction of highly active antiretroviral therapy, there has been no significant improvements in survival, tumor control, or better tolerability of chemoradiation therapy. 14 The anal Papanicolaou (Pap) test is a recommended primary screening procedure used to detect precancerous changes in the anal canal. Similar to the cervix, the anal canal has a transformation zone that is vulnerable to dysplasia from HPV infection. 15 Suggested screening guidelines first released by the New York State Department of Health AIDS Institute recommend targeted annual anal cancer screening with anal Pap tests for MSMs, all HIV-infected patients with a history of anogenital warts, and HIV-infected women with a history of cervical or vulvar dysplasia. 16, 17 Any abnormal findings of any grade should be referred for high-resolution anoscopy along with anal biopsy. 18 Sigel et al 19 proposed a conceptual model for cancer screening in HIV-infected patients where the benefits and harms of screening are considered for individualized patient care (Figure 1) . Specifically, 3 factors should be considered for a screening program in this group: (1) the patient"s age-related life expectancy based on comorbid conditions, (2) the patient"s individual cancer risk, and (3) an estimate of the harms and benefits associated with the screening. 19 A cancer screening test should provide increased life expectancy while decreasing morbidity risk.
Currently, no randomized controlled trials have been conducted to test the reliability and validity of a screening program for anal cancer. Albeit unproven, screening procedures for anal dysplasia may have the same success of decreasing mortality and morbidity that has been seen with cervical cancer. 20 Despite the lack of conclusive evidence and formal screening guidelines, some clinics have implemented screening programs for anal cancer in an effort to alter the increasing clinical burden of anal cancer in HIV-infected individuals. 16, 20 Screening for anal cancer may be beneficial in cancer prevention but requires multiple visits that include the Pap screening test, referral to follow-up anoscopy after an abnormal Pap test, and the possible treatment of precancerous lesions. Adequate screening and follow-up of anal dysplasia in HIV-infected individuals are needed for a successful cancer prevention plan. However, the factors associated with anoscopy screening and follow-up for anal cancer have been virtually unstudied in the HIV-infected population, a population who bears the greatest risk for HPV-related cancers. Previous studies found that highrisk groups such as HIV-infected MSMs, women with a history of cervical dysplasia, individuals with low CD4 counts, individuals older than 45 years, current smokers, and individuals who engage in anoreceptive intercourse are at a considerable risk for anal cancer and may benefit from screening. 21Y23 Our study sought to examine whether these factors were predictors of anal cancer screening and follow-up. Therefore, the purposes of this study are, first, to describe anal cancer screening and follow-up rates after an abnormal anal Pap test and, second, to examine the sociodemographic predictors of anal cancer screening and follow-up in a sample of HIV-infected individuals.
n Methods
Study Design and Sample Size
This study was a retrospective chart review of electronic medical records of HIV-infected individuals enrolled at a large comprehensive metropolitan HIV care Infectious Disease Program (IDP) between January 2010 and December 2013. The sample size for the chart review was determined by using the recommendations set by Gearing et al. 24 The authors propose that the expected proportion within the population that will have the measure of interest is greater than 50% and to sample 10% of this proportion, as a good rule of thumb, to obtain a sample size for chart audits. A total of 3134 patients were seen at the clinic during the study's sampling time frame. Thus, it is estimated that 1500 of these patients were to have a history of anal dysplasia; therefore, the original target sample size for this review was 150 medical charts. For this study, the sample size was increased to 200 medical charts to better capture screening and follow-up rates in this population.
Study Setting and Sample
The target sample population was patients managed at a large metropolitan HIV clinic located in the southeast region of the United States. This clinic offers its patients on-site subspecialty care including anal Pap tests and follow-up with high-resolution anoscopy. Using a random number generator, electronic medical records were randomly selected from a generated patient list of male and female patients seen at the clinic within the study's period. The time frame for this study was selected to correspond with the approximate time HPV testing was commonly made available in the clinical setting. The inclusion criteria for the medical record to be reviewed were as follows: (1) managed and enrolled in the IDP between January 2010 and December 2013, (2) received ongoing primary care at the clinic within the study's period, and (3) 18years or older. Medical records that did not have at least 2 documented clinic visits within the study period were excluded.
A preliminary analysis found an underrepresentation of women in the chart review. To capture more women and with permission from the study's principal investigator, we used a random selection of participants from a list of unlinked medical record numbers from the closed KHARMA (Keeping Healthy and Active with Risk reduction and Medication Adherence) study. 25 The KHARMA study was a randomized controlled behavioral clinical trial that enrolled 207 HIV-infected women managed at the IDP. Using the clinic"s generated patient list and de-identified and unlinked medical record numbers from the KHARMA study, medical records were randomly selected and reviewed until a sample of 200 was reached ( Figure 2 ).
Data Collection
After approval from the university's institutional review board and from the hospital's Research Oversight Committee, data collection was conducted using a standardized data abstraction instrument created by the investigator. Electronic medical records were reviewed for demographic information including age, race/ ethnicity, gender, and insurance status. Medical notes were reviewed for information on date of HIV diagnosis, marital or partner status, smoking status, and sexual orientation. Laboratory results were reviewed for the patient"s most recent CD4 + cell counts. Laboratory and biopsy results were reviewed for history of anal Pap testing and follow-up with high-resolution anoscopy within the 3-year time frame of the study. Medical notes were also reviewed for documented anal Pap testing and/or referral for follow-up anoscopy. An anal Pap test or follow-up anoscopy was recorded as absent if it was not documented as performed, either by a clinic provider or an outside clinic provider. Data were abstracted by 4 reviewers under the supervision of the investigator. For quality control, approximately 10% of the Figure 2 n Electronic medical record selection and exclusion. medical records were audited by the investigator to assure agreement of coding, and all data were double-entered.
Data Analysis
Statistical analyses were conducted using IBM SPSS Statistics 20. 26 Demographic information was examined using descriptive analyses such as means, frequencies, and standard deviations. Pearson's r was used to examine bivariate associations between sociodemographic factors and anal cancer screening and follow-up anoscopy. Variables that showed association with the event in bivariate analysis with PG .20 were included in the logistic regression model. Multiple logistic regressions were used to model receipt of anal Pap tests and follow-up with anoscopy. Two predictive models were built: the dependent variable in the first model was whether an individual received an anal Pap test within the study period (yes/no); the second model was whether an individual received a follow-up anoscopy after an abnormal anal Pap test (yes/no). Variables that were significant at PG .05 were kept in the final model.
n Results A total of 342 medical records were randomly selected and reviewed using the inclusion criteria; 142 medical records did not meet the inclusion criteria and were excluded. Of the 200 medical records, 99 were female, and 101 were male. Most of the sample were documented as black (74%), nonsmokers (47.5%), and single/not married (66%) and reported Medicare as the primary source of health insurance (38.5%). The mean reported age was 49.7years (range, 25Y76years; Table 1 ).
Only 29% of the sample (n=58) had a documented anal Pap test during the study period. Of the individuals with a documented anal Pap test, 70% (n=40) had an abnormal anal Pap, and 93% (n=37) were recommended for follow-up with an anoscopy. Sixty-five percent of the men and women (n=24) recommended for anoscopy did not have a documented follow-up anoscopy (Figure 3) .
Gender (r=j0.41, P=.00), MSMs (r=0.43, P=.00), CD4 + cell count (r=j0.10, P=.14), and age (r=j0.26, P=.00) met the bivariate criteria and were entered into the model using backward stepwise approach to predict occurrence of anal Pap test screening. For model 2, gender (r=j0.14, P=.06), health insurance (r=j0.12, P=.13), MSMs (r=0.30, P=.00), CD4 + cell count (r=j0.10, P=.20), and age (r=j0.15, P=.05) were selected and entered into the logistic regression model using backward stepwise approach to predict anoscopy follow-up (Table 1) . It is important to note that gender and MSMs were highly correlated in this analysis (r=j0.55, P=.00).
The final regression model indicated that gender and MSMs significantly predicted receipt of an anal Pap test. Women were less likely to be screened for anal cancer (odds ratio [OR], 0.24; P=.00), whereas MSMs are almost 4 times more likely to be screened for anal cancer (OR, 3.7; P=.02). Men who have sex with men were included in the final model as an independent predictor of follow-up anoscopy after an abnormal anal Pap test, where MSMs were 6 times more likely to have an anoscopy after an abnormal anal Pap test compared with heterosexual men or women of any sexual orientation (OR, 6.88; P=.00; see Table 2 ).
n Discussion
The goal of anal cancer screening is to capture and treat anal intraepithelial neoplasia (AIN) II and III before progression to carcinoma. 27 Our exploratory study found that anal cancer screening is performed at low rates and, in addition, revealed a considerable breakdown in follow-up care after an abnormal anal Pap test. A previous study examined an agreement between anal Pap cytology and histopathology and found that 40% of a 1732 HIV-infected cohort (n=642) received repeat Pap testing within 3years of the anal Pap smear. 28 Our study found that only 29% of the sample had a history of an anal Pap test and only 46% of those who were recommended for follow-up actually received follow-up anoscopy. The reasons for low follow-up rates warrant further examination in future studies. Although no formal guidelines for anal cancer screening are established, increased efforts are needed to ensure patients who are screened receive the necessary follow-up and treatment as part of a cancer prevention plan. One observational study found that the median time from progression of high-grade AIN to cancer was 8.6months for participants who did not receive the necessary follow-up anoscopy. 29 Men who have sex with men and gender were significant predictors of anal cancer screening. Despite overall low screening rates in this study, we found that the high-risk group, MSMs, is nearly 4 times more likely to be screened for anal cancer. Anal cancer screening may be highly beneficial in this group where a study with a sample of MSMs found anal HPV infection to be as high as 93% among HIV-infected men compared with 60% among HIV-uninfected men. 28 Our findings reveal that this high-risk group is being captured for anal cancer screening at the IDP.
Similar to MSMs, HIV-infected women with a history of cervical dysplasia are considered a high-risk group because of an increased risk for AIN and are recommended to be screened for anal cancer. 23 Despite that 65% of the women in this study had a documented history of an abnormal cervical Pap test, they were less likely to be screened for anal cancer. Human immunodeficiency virusYinfected women in this study are a high-risk group for anal cancer and yet are not being captured for anal cancer screening. In fact, Kojic et al 30 found anal HPV infection to be more common than cervical HPV in both HIV-infected and HIV-uninfected women. This finding suggests the need for increased anal cancer screening efforts in HIV-infected women where there is a high incidence of abnormal cervical Pap smears. Human immunodeficiency virusYinfected women may benefit from a targeted anal cancer screening program similar to that for HIV-infected MSMs. It is essential to provide the necessary resources and cancer prevention strategies to help decrease the personal costs and burden from anal cancer in HIV-infected women.
Similar to many cancers, the risk for anal cancer increases with age, and the median age for anal cancer is greater than 50 years. Because of the effects of HIV treatment, HIV-infected persons are living longer and experiencing more comorbidities associated with aging. Although age did not enter our model as a predictor for anal cancer screening or follow-up, there was a significant relationship between age and screening. Those who received an anal Pap test had a younger mean age (45.88years) than those who did not have a documented anal Pap test (51.55 years; t=3.749, P=.00.) Therefore, important screening in an aging HIV-infected population may be omitted, and more research to examine reasons for this is warranted.
Men who have sex with men was the only significant predictor in the final model for receiving a follow-up anoscopy. Men who have sex with men were 6 times more likely to receive Figure 3 n Anal cancer screening and follow-up patterns in men and women with HIV. follow-up care after an abnormal anal cancer Pap test. Given that HIV-infected MSMs carry the greatest burden for anal cancer incidence, it is very likely that this group is often managed and followed more closely to monitor for acquired immunodeficiency syndromeYrelated disease.
COST-EFFECTIVENESS OF ANAL CANCER SCREENING
To date, there is no randomized clinical trial to support the rationale for an anal cancer screening program. The benefits of screening for anal cancer are inferred from the success of the national cervical cancer screening program. Goldie et al 31 evaluated the cost-effectiveness of screening HIV-infected MSMs for anal dysplasia using a transition Markov model. The authors found that performing annual anal Pap testing was the most cost-effective screening method and provided almost a 3-month gain in quality-adjusted life year (QALY), compared with no screening, with a cost-effectiveness ratio of $13000 per QALY saved. Similarly, Ong et al 32 evaluated the cost-effectiveness of screening for anal cancer using digital rectal examinations in HIV-infected MSMs. The average lifetime cost of screening and managing anal cancer ranged from $373 for no screening to $4468 for annual screening of men older than 50years. Qualityadjusted life years gained for no screening was 35.11 versus 35.24 for annual screening of men 50years or older. Qualityadjusted life year was also calculated and compared among no screening and several screening strategies, and it was found that all screening strategies for anal cancer increased the number of gained QALYs. The authors concluded that regular anal screening for HIV-infected MSMs 50 years or older may be costeffective and should be implemented. Another study found anal cancer screening to be cost-effective when compared with no screening for high-risk HIV-infected women. 33 
HPV VACCINATION
Human papillomavirus vaccination may be another effective strategy for cancer prevention in this population. The quadrivalent HPV vaccine has been shown to be efficacious against anal HPV infections, including in high-risk groups such as MSMs and HIV-infected men and women. 34Y37 Specifically, a substudy of a larger double-blind randomized trial of MSMs (aged 16-26years) found the quadrivalent HPV vaccine to be efficacious in reducing the incidence of persistent anal infection associated with HPV types 6, 11, 16, and 18. 36 The efficacy against HPV types 6, 11, 16, and 18 was 50.3%, and the rate of infection from the 4 types was reduced by 48.5%. In addition, a significant reduction in persistent anal HPV caused by the 4 types was reduced by 59.4% in this sample. The safety profile is favorable where no vaccine-related adverse events were reported. The authors concluded that the quadrivalent vaccine can be a useful tool to prevent HPV-related disease and potentially even cancer in the high-risk MSM population.
Currently, the Advisory Committee on Immunization Practices recommends routine 2-dose HPV vaccination to start at 11 or 12years old. Women should be vaccinated through the age of 26years and up to the age of 21years for men who were not previously vaccinated. However, vaccination with 3 doses is recommended up to the age of 26 years for HIV-infected individuals and MSMs.
IMPLICATIONS FOR PRACTICE
Despite the lack of formal guidelines to support anal cancer screening, there is compelling evidence that screening with anal Pap testing may be beneficial in high-risk groups. It is imperative for advanced practice nurses, nurses, and other members of the healthcare team to identify high-risk groups that may benefit from anal cancer screening (ie, HIV-infected men and women, MSMs, and women with a history of high-grade cervical dysplasia). Diligent follow-up of those who screen abnormal is also important, and patients should be connected to cancer preventative resources for screening and any necessary follow-up care. Evidence-based patient education should be included in the care and management of HIV-infected individuals and include information regarding anal cancer risk, HPV, and HPV vaccination. Finally, there is a need for more evidence-based educational programs to improve understanding of anal cancer risk and to improve screening.
Limitations
The main limitation of this study is that data pertaining to other determinates of anal cancer screening and follow-up such as social support, HIV-related stigma, health beliefs, knowledge, or provider-related factors were unable to be captured in the medical record review. In addition, data were not available for every variable in every medical record, which presents a missing data bias. It is important to note that sexual orientation was only documented if the patient was an MSM. Sexual practices for women were not documented in the medical records. Thus, gender and MSMs were highly correlated and may jointly predict anal cancer screening and follow-up. More data are required to tease apart the effect of each variable. Finally, the sample population was enrolled at a comprehensive IDP in a highresource setting with trained clinicians, cytology, anoscopy, biopsy, and necessary treatment available for its patients. This setting and its sample may not be a representative sample of the general HIVinfected population. However, this bias would suggest the possibility of even lower rates of anal cancer screening and follow-up in less resource-intensive settings. Despite these limitations, this study provided new findings of the sociodemographic risk factors for anal cancer screening and anoscopy follow-up.
n Conclusions Currently, no previous studies were found that examined the sociodemographic predictors of anal cancer screening and follow-up after an abnormal anal Pap among HIV-infected individuals. Our study addressed this gap and found that sexual orientation and gender were independent predictors of anal cancer screening and follow-up anoscopy. Findings from this study can inform strategies to improve screening rates, especially for HIV-infected women, in efforts to decrease anal cancer morbidity and mortality. Cancer prevention is a multistep process that requires both screening and follow-up efforts, and healthcare providers play a vital role in these efforts. The healthcare team is responsible for coordinating and providing care for HIVinfected patients and is at the forefront of facilitating adherence to screening and follow-up care. Future research should be directed at examining the multifactorial predictors of anal cancer screening and follow-up anoscopy in efforts to increase screening in individuals infected with HIV. All high-risk groups for anal cancer should be targeted for preventative measures as part of a cancer prevention plan to decrease the personal and clinical burden associated with anal cancer.
